Mark E. Robson
Memorial Sloan Kettering Cancer Center · 941 works · 59,262 citations · h-index 113
Top works
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- A note on competing risks in survival data analysis
- Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
- Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
- American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
- BRCA-associated breast cancer in young women.
- The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
- MRI of Occult Breast Carcinoma in a High-Risk Population
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
- Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.
- Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
- Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1 / 2 (CIMBA)
- Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes